<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305756</url>
  </required_header>
  <id_info>
    <org_study_id>130494</org_study_id>
    <nct_id>NCT04305756</nct_id>
  </id_info>
  <brief_title>Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery</brief_title>
  <official_title>Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of two dosing regimens of low molecular
      weight heparin (LMWH) to reach prophylactic anti-factor Xa levels in post-cesarean delivery
      women. Half of participants will receive a fixed dose of LMWH, while the other half will
      receive a weight-based dose. The hypothesis is that the use of a weight-based dose will
      result in more women reaching prophylactic levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Venous thromboembolism (VTE) is a major contributor to maternal morbidity and mortality. The
      immediate postpartum period is a high risk time for VTE, and cesarean delivery is an
      additional risk factor. In the United States, use of postpartum VTE prophylaxis with
      low-molecular weight heparin (LMWH) is commonly used but without a standard protocol or dose
      across all hospitals. A fixed-dose of LMWH is frequently used based on data from
      non-obstetric studies. However, there are concerns that in the postpartum population this
      fixed dose may not be adequate for prophylaxis.

      This study aims to evaluate the efficacy of fixed dose versus weight-based LMWH to reach
      prophylactic anti-Xa levels in post-cesarean delivery women. This will be a randomized
      controlled trial (RCT) with half of participants receiving a fixed dose of LMWH and half of
      participants receiving a weight-based dose of LMWH. The hypothesis is that the use of a
      weight-based LMWH compared to a fixed dose will result in more women achieving prophylactic
      anti-Xa levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2020</start_date>
  <completion_date type="Anticipated">March 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prophylactic peak anti-Xa level</measure>
    <time_frame>Postoperative day #3 at peak (4-6 hours post-dose)</time_frame>
    <description>Anti-Xa level in prophylactic range (0.2 to 0.6 IU/mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Venous thromboembolism</measure>
    <time_frame>From delivery through 6 weeks postpartum</time_frame>
    <description>Presence of venous thromboembolism as confirmed on diagnostic imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound Complications</measure>
    <time_frame>From delivery through 6 weeks postpartum</time_frame>
    <description>Post-cesarean wound hematoma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Thromboembolism</condition>
  <condition>Postpartum DVT</condition>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>Weight-based LMWH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a weight-based dose of prophylactic enoxaparin.
- For all BMI groups: 0.5mg/kg rounded to the nearest 10mg will be injected subcutaneously every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed LMWH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a fixed dose of prophylactic enoxaparin.
For BMI &lt;40: 40mg injected subcutaneously every 24 hours
For BMI &gt; or = to 40: 40mg injected subcutaneously every 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Low molecular weight heparin</description>
    <arm_group_label>Fixed LMWH</arm_group_label>
    <arm_group_label>Weight-based LMWH</arm_group_label>
    <other_name>Lovenox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cesarean delivery

          -  Meet facility guidelines for postpartum venous thromboembolism (VTE) prophylaxis:
             Presence of 1 major, or 2 or more moderate, risk factors.

          -  Major risk factors: history of venous thromboembolism, high risk thrombophilia, BMI
             â‰¥40, high risk medical comorbidities (heart disease, sickle cell disease, systemic
             lupus erythematosus, inflammatory bowel disease), cesarean hysterectomy, nephrotic
             range proteinuria, or cesarean intrapartum/during labor

          -  Moderate risk factors: BMI &gt; 30, multifetal pregnancy, postpartum hemorrhage (&gt;1L
             blood loss), tobacco use, non-laboring or elective cesarean, preeclampsia, infection,
             preterm delivery (&lt; 37 weeks gestational age), age &gt; 35 years, low risk thrombophilia,
             family history of venous thromboembolism, stillbirth, varicose veins, prolonged labor
             (&gt; 24 hours)

        Exclusion Criteria:

          -  Contraindication to anticoagulation

          -  Plan for therapeutic anticoagulation (antepartum or postpartum)

          -  Known renal dysfunction (Creatinine clearance &lt; 30 mL/minute)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torri Metz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann Bruno, MD</last_name>
    <phone>801-581-8425</phone>
    <email>ann.bruno@hsc.utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Gibson</last_name>
    <phone>801-213-2845</phone>
    <email>marie.gibson@hsc.utah.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Szczotka</last_name>
      <email>kathryn.szczotka@hsc.utah.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Factor Xa</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Enoxaparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

